BURLINGTON, Mass., Sept. 25, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Dr. Brian Schwartz, Head of Research and Development and Chief Medical Officer, will present at the Leerink Partners 4th Annual Rare Disease Roundtable on September 30th, 2015 at 12:55 p.m. ET at Le Parker Meridian Hotel in New York, New York.
You can access the live webcast of the presentation via the “Investors and Media” section of our website, www.arqule.com, under “Events”. A replay of the webcast will be available shortly after the conclusion of the presentation.
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family; and ARQ 761, a Beta lapachone analog being evaluated as a promoter of NQ01-mediated programmed cancer cell necrosis. ArQule’s current discovery efforts are focused on the identification of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds.
Contacts: Dawn Schottlandt Sr. Director, Investor Relations/ Corp. Communications (781) 994-0300 www.ArQule.com